Lilly swoops on Dermira to claim Dupixent rivalEli Lilly agreed on Friday to buy dermatology specialist Dermira for $1.1 billion and its lead drug, a Share XLilly swoops on Dermira to claim Dupixent rivalhttps://pharmaphorum.com/news/lilly-swoops-on-dermira-to-claim-dupixent-rival/
Regeneron/Sanofi get EU okay for Dupixent in “asthma of the sinuses”Regeneron and Sanofi’s immunology drug Dupixent has been approved for a third indication in Europe, adding the treatment Share XRegeneron/Sanofi get EU okay for Dupixent in “asthma of the sinuses”https://pharmaphorum.com/news/regeneron-sanofi-get-eu-okay-for-dupixent-in-asthma-of-the-sinuses/
Pfizer’s Xeljanz follow-up abrocitinib gathers momentumPfizer has reported new data with abrocitinib, a follow-up to its JAK inhibitor Xeljanz, which is facing increased Share XPfizer’s Xeljanz follow-up abrocitinib gathers momentumhttps://pharmaphorum.com/news/pfizers-xeljanz-follow-up-abrocitinib-gathers-momentum/
Sanofi’s Dupixent backed for nasal polyps use in EuropeSanofi and Regeneron’s fast-growing immunology drug Dupixent is on course for a third indication in Europe after being Share XSanofi’s Dupixent backed for nasal polyps use in Europehttps://pharmaphorum.com/news/sanofis-dupixent-backed-for-nasal-polyps-use-in-europe/
Sanofi’s eczema drug gets EU approval to treat adolescentsThe European Commission (EC) has extended the marketing authorisation for Sanofi and Regeneron’s eczema drug Dupixent (dupilumab) to Share XSanofi’s eczema drug gets EU approval to treat adolescentshttps://pharmaphorum.com/news/sanofi-eczema-drug-gets-eu-approval-adolescents/
Almirall gets in on the eczema actionSanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall Share XAlmirall gets in on the eczema actionhttps://pharmaphorum.com/views-analysis-market-access/almirall-gets-in-on-the-eczema-action/
Sanofi/Regeneron asthma trial casts doubt on IL-33 class prospectsThe good news for Sanofi and Regeneron is that their interleukin-33-targeting drug seems to work in asthma. The Share XSanofi/Regeneron asthma trial casts doubt on IL-33 class prospectshttps://pharmaphorum.com/news/sanofi-regeneron-asthma-trial-casts-doubt-il-33-class-prospects/
Sanofi claims EU okay for Dupixent in asthmaSanofi and partner Regeneron have picked up an approval in Europe for Dupixent in asthma, unlocking an important Share XSanofi claims EU okay for Dupixent in asthmahttps://pharmaphorum.com/news/sanofi-claims-eu-okay-for-dupixent-in-asthma/
Sanofi/Regeneron’s Dupixent shows more promise in nasal polypsSanofi and Regeneron’s attempts to make Dupixent into a blockbuster franchise have been boosted with more strong phase Share XSanofi/Regeneron’s Dupixent shows more promise in nasal polypshttps://pharmaphorum.com/news/sanofi-regenerons-dupixent-shows-more-promise-in-nasal-polyps/
